The pharmaceutical industry is at a structural inflection point. For decades, drug development has been plagued by Eroom’s Law, where the cost of developing a new drug doubles roughly every nine years. The core investment case for AIDD is a compression of the cost-and-time curve defined by Eroom’s Law. Any company that can credibly demonstrate that AI-originated candidates fail less often than traditionally discovered ones will have an advantage in the pharmaceutical industry.

Written by Abby Hsu and Denise Pan

Edited by Gabriel Abrams and William Wu

Physical AI is entering a period of rapid transition. After decades in which robotics remained largely confined to structured industrial environments, a convergence of advances in computer vision, manipulation, and foundation models has opened the door to general-purpose robots capable of operating in unstructured, real-world settings. Humanoid robots are no longer a speculative technology; they are being deployed, funded, and trained at scale by some of the most serious technical teams in the world. But the bottleneck is not the robots; it is everything underneath them.

Written by Satvika Singh

Edited by Gabriel Abrams and William Wu